|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000100 USD | +9,900.00% |
|
0.00% | - |
| 12-28 | Motion for Asset Sale Approved for Seelos Therapeutics, Inc. | CI |
| 25-10-21 | GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q). | CI |
Company Valuation: Seelos Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Market Cap 1 | 36.11 | 84.41 | 172 | 72.77 | 13.61 |
| Change | - | 133.74% | 103.72% | -57.68% | -81.29% |
| Enterprise Value (EV) 1 | 25.85 | 78.47 | 112.2 | 77.36 | 24.85 |
| Change | - | 203.54% | 42.96% | -31.04% | -67.88% |
| P/E Ratio | - | -3.7x | -2.24x | -0.98x | -0.18x |
| PBR | -5,174x | 33.5x | 3x | -6.86x | -0.41x |
| PEG | - | - | -0x | 0.2x | 0x |
| Capitalization / Revenue | 96,298,285x | - | - | - | 6,179,954x |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | -0.93x | - | - | - | - |
| EV / EBIT | -0.93x | -4.18x | -1.82x | -1.09x | -0.61x |
| EV / FCF | -2.79x | -4.82x | -3.7x | -2.17x | -4.86x |
| FCF Yield | -35.8% | -20.8% | -27% | -46% | -20.6% |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | - | -1,638 | -2,790 | -2,655 | -989.5 |
| Distribution rate | - | - | - | - | - |
| Net sales | 0.375 | - | - | - | 2.203 |
| EBITDA 1 | -27.71 | - | - | - | - |
| EBIT 1 | -27.75 | -18.76 | -61.67 | -70.92 | -40.5 |
| Net income 1 | -51.26 | -19.1 | -66.05 | -73.53 | -37.88 |
| Net Debt 1 | -10.26 | -5.938 | -59.78 | 4.589 | 11.23 |
| Reference price 2 | 5,145.605269 | 6,067.206212 | 6,259.206409 | 2,607.362669 | 177.920000 |
| Nbr of stocks (in thousands) | 7.02 | 13.9 | 27.5 | 27.9 | 76.5 |
| Announcement Date | 3/17/20 | 3/11/21 | 3/4/22 | 3/10/23 | 3/6/24 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 136 | |
| 33.17x | 8.64x | 26.13x | 0.05% | 56.42B | |
| 16.69x | 5.03x | 10.91x | 1.8% | 44.54B | |
| -17.8x | 4.17x | -7.3x | -.--% | 22.9B | |
| -36.36x | 12.23x | -35.67x | -.--% | 21.21B | |
| 20.25x | 3.95x | 10.26x | -.--% | 16.4B | |
| 21.44x | 4.3x | 14.23x | -.--% | 15.4B | |
| 16.8x | 4.85x | 11.36x | -.--% | 13.35B | |
| -433.48x | 29.5x | -3289.39x | -.--% | 12.36B | |
| 36.9x | 14.16x | 41.61x | 0.18% | 11.15B | |
| Average | -38.04x | 9.65x | -357.54x | 0.23% | 21.37B | |
| Weighted average by Cap. | -12.27x | 8.35x | -180.62x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SEEL.Q Stock
- Valuation Seelos Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
